Preoperative CT evaluation of adrenal glands in non-small cell bronchogenic carcinoma

Nielsen, M.; Dk, Heaston; Dunnick, N. Reed; Korobkin, Melvyn

doi:10.2214/ajr.139.2.317

Cited by 83 publications

(26 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other imaging options include in and out of phase MRI,42 [2+] non-contrast43 [3] and washout CT 44. [2+] Biopsy specimens may be obtained by percutaneous techniques,45 [3] endoscopic ultrasound or laparoscopy.…”

Section: Section 1: Selection Of Patients For Radical Treatmentmentioning

confidence: 99%

Guidelines on the radical management of patients with lung cancer

Lim

Baldwin²,

Beckles³

et al. 2010

Thorax

398

343

View full text Add to dashboard Cite

Section: Section 1: Selection Of Patients For Radical Treatmentmentioning

confidence: 99%

Guidelines on the radical management of patients with lung cancer

Lim

Baldwin²,

Beckles³

et al. 2010

Thorax

398

343

View full text Add to dashboard Cite

“…[44][45][46][47] Although adrenal adenomas are readily characterized on unenhanced CT by detecting the presence of fat (a mean attenuation value of less than 10 HU) or on enhanced CT 48,49 by demonstrating a fall in attenuation of 50% or greater on a 10-min delayed scan, indeterminate adrenal nodules are common, and require further evaluation by MRI, biopsy, or PET scanning. On PET or PET/CT imaging, the finding of FDG uptake within the adrenal gland greater than that of the liver is a highly sensitive and specific sign of adrenal metastatic disease, [50][51][52] with an overall diagnostic accuracy of greater than 92%.…”

Section: Descriptormentioning

confidence: 99%

PET/CT Imaging of Lung Cancer

Bruzzi

Munden

2006

Journal of Thoracic Imaging

View full text Add to dashboard Cite

Fluoro-deoxyglucose positron emission tomography (PET) imaging has a diagnostic and prognostic value in the initial staging, restaging, and surveillance of non-small-cell lung cancer (NSCLC). When used in conjunction with conventional radiologic imaging, PET imaging has been shown to result in significant changes in clinical management of NSCLC. Specifically, baseline PET imaging can improve initial staging and guide surgical and radiotherapy planning, whereas repeat PET imaging after the initiation of chemoradiotherapy can predict tumor response and help tailor therapy. After the end of definitive treatment, PET has greater diagnostic accuracy than other imaging modalities for the detection of tumor recurrence. The recent development of fused PET/CT imaging has improved the radiologic evaluation of NSCLC patients by combining metabolic and anatomic imaging; however, this has resulted in more complexity in the image interpretation. It is important for the interpreting physician to understand the role PET/CT plays in the staging, assessment of treatment, and follow-up after therapy in the multidisciplinary management of patients with NSCLC.

show abstract

“…NSCLC metastasizes to the adrenal glands in approximately 15–25% of cases [74]; however, two thirds of adrenal masses in NSCLC patients are found to be benign adenomas [75, 76]. Similarly, 5% of patients with potentially operable NSCLC exhibited liver metastases.…”

Section: Non-small-cell Lung Cancermentioning

confidence: 99%

“…Similarly, 5% of patients with potentially operable NSCLC exhibited liver metastases. Thus, detection of an isolated adrenal or hepatic mass by ultrasound or CT scan in patients with NSCLC may require biopsy to rule out metastatic disease [74, 75]. …”

Section: Non-small-cell Lung Cancermentioning

confidence: 99%

Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer

Schiller

2001

Oncology

140

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related death in the United States, accounting for over 30% of cancer deaths in men and 25% in women. Small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are uniformly aggressive tumors, with rates of regional or distant metastases at diagnosis as high as 70%. Because the majority of these tumors are unresectable, patients with relatively good performance status receive platinum-based chemotherapy. Although no treatment consensus exists, currently recommended regimens for SCLC include PE (cisplatin and etoposide), CAV (cyclophosphamide, doxorubicin, and vincristine), CAE (cyclophosphamide, doxorubicin, and etoposide), and CAVE (cyclophosphamide, doxorubicin, vincristine, and etoposide). Of these, the PE regimen has been widely accepted in the United States, although CE (carboplatin and etoposide) provides better tolerability. For NSCLC, standard chemotherapy regimens have included platinum-based therapy (cisplatin and a vinca alkaloid or PE). Data from recent studies suggest that the addition of paclitaxel to platinum modestly improves tumor response and survival in NSCLC. Although SCLC and NSCLC are both responsive to first-line chemotherapy, most patients relapse and die from their disease, with 5-year survival rates of approximately 15%. Given the disappointing survival rates associated with SCLC and NSCLC, the introduction of new cytotoxic agents has been eagerly anticipated. Evidence of improved response and extended survival is mounting for various combinations of established regimens (e.g., PE) with newer drugs exhibiting novel mechanisms of action and single-agent antitumor activity, such as gemcitabine, paclitaxel, docetaxel, vinorelbine, and topotecan. This article reviews the current standards of care in SCLC and NSCLC, and introduces the potential role of newer agents given in combination with standard chemotherapy.

show abstract

Preoperative CT evaluation of adrenal glands in non-small cell bronchogenic carcinoma

Cited by 83 publications

References 14 publications

Guidelines on the radical management of patients with lung cancer

Guidelines on the radical management of patients with lung cancer

PET/CT Imaging of Lung Cancer

Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer

Contact Info

Product

Resources

About